Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Docetaxel/Gemcitabine in NSCLC
NCT00193427Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Apr 2004
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and gemcitabine in non-small cell lung cancer (NSCLC), sponsored by SCRI Development Innovations. Primary endpoint: Pathologic Complete Response Rate at 18 months. Started Apr 2004; status: completed.
02
Drugs
docetaxelgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00193427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193427.